A European Medicines Agency (EMA) panel recommended granting marketing approval to the diabetes drug Steglatro developed by Merck & Co. Inc. and Pfizer Inc.
AstraZeneca said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late-stage trial that could challenge GlaxoSmithKline’s new three-in-one inhaler.
Gene testing company Illumina won a jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a Roche subsidiary, of using patented prenatal testing technology without authorization.
Seniors who get a flu shot every year are less likely to be hospitalized with severe influenza infections or to die from them than those who get vaccinated only sporadically, a study suggests.
Biogen acquired an IND-ready asset from Karyopharm Therapeutics for $10 million upfront.
Two former executives of Sanofi and Merrimack Pharmaceuticals launched Partner Therapeutics (PTx) to focus on oncology.
Takeda Pharmaceutical and development partner Zinfandel Pharmaceuticals pulled the plug on their five-year Phase III TOMMORROW trial following an interim analysis.
Amneal Pharmaceuticals is planning an expansion of its New York facilities that will create hundreds of jobs as the company and Impax Laboratories near completion of a planned merger.
ProMIS Neurosciences Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced it has issued a new scientific white paper entitled: ‘Not all Amyloid Beta Therapeutics are Created Equal’.